IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer
17 Maio 2023 - 9:00AM
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage
biopharmaceutical company focused on innovative gamma-delta T cell
therapies, today announced positive preclinical data underscoring
the potential of its DeltEx Gamma-Delta T cells to target and kill
ovarian cancer. The data were featured in a poster presentation at
the American Society of Cell & Gene Therapy (ASGCT) 26th Annual
Meeting and showed that DeltEx Gamma-Delta T cells were able to
target and kill ovarian cancer cells, even in platinum-resistant
and treatment-resistant cell lines.
“These findings highlight the synergy of
combining gamma-delta T cells with chemotherapy to target solid
tumors, even outside the brain,” said William Ho, CEO and
co-founder of IN8bio. “We are encouraged by these data that suggest
that a combination using DeltEx Gamma-Delta T cells may provide a
promising new approach to treating patients with ovarian
cancer.”
IN8bio’s DeltEx Drug Resistance Immunotherapy,
or DeltEx DRI, gamma-delta T cells are engineered to be more
effective at killing cancer cells. These cells are designed to be
resistant to the killing effects of chemotherapy, allowing them to
remain functional and be used concurrently in combinations to
create a strong synergistic tumor killing effect. The preclinical
data demonstrates that temozolomide (TMZ), an alkylating agent that
creates DNA double-stranded breaks, can work synergistically in
combination with poly ADP-ribose polymerase inhibitors (PARPi) to
significantly increase NKG2D ligand (NKG2D-L) expression. NKG2D-L
are proteins that make cancer cells more visible to the immune
system, particularly to gamma-delta T cells, and resulted in
greater killing of ovarian cancer cells, even in platinum-resistant
and treatment-resistant ovarian cell lines.
Lawrence Lamb, Ph.D., co-founder and Chief
Scientific Officer of IN8bio, expressed great optimism about the
broad implications of this research and approach, "These data serve
as a compelling proof-of-concept, demonstrating how gamma-delta T
cell biology could seek out and eradicate tumor cells across a
broad range of challenging cancer indications.” In addition, "We
are encouraged by these results and look forward to evaluating the
applicability of INB-400 in ovarian cancer and other solid tumor
targets as soon as possible.”
About INB-400
INB-400 is IN8bio’s DeltEx chemotherapy
resistant autologous and allogeneic drug resistant immunotherapy
(DRI) technology. Allogeneic INB-400 will expand the application of
DRI gamma-delta T cells into other solid tumor types through the
development of allogeneic or “off-the-shelf” DeltEx DRI
technology.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization
of gamma-delta T cell product candidates for solid and liquid
tumors. Gamma-delta T cells are a specialized population of T cells
that possess unique properties, including the ability to
differentiate between healthy and diseased tissue. IN8bio’s DeltEx
platform employs allogeneic, autologous, iPSC and genetically
modified approaches to develop cell therapies, designed to
effectively identify and eradicate tumor cells.
IN8bio is currently conducting two
investigator-initiated Phase 1 clinical trials for its lead
gamma-delta T cell product candidates: INB-200 for the treatment of
newly diagnosed glioblastoma (GBM) and INB-100 for the treatment of
patients with leukemia undergoing hematopoietic stem cell
transplantation. IN8bio is initiating INB-400, a company-sponsored
Phase 2 clinical trial in newly diagnosed GBM, which received IND
clearance in late 2022. IN8bio also has a broad portfolio of
preclinical programs focused on addressing other hematological and
solid tumor cancers. For more information about IN8bio and its
programs, please visit www.IN8bio.com.
Forward Looking StatementsThis
press release may contain forward-looking statements made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These statements may be identified by words
such as “aims,” “anticipates,” “believes,” “could,” “estimates,”
“expects,” “forecasts,” “goal,” “intends,” “may,” “plans,”
“possible,” “potential,” “seeks,” “will” and variations of these
words or similar expressions that are intended to identify
forward-looking statements, although not all forward-looking
statements contain these words. Forward-looking statements in this
press release include, but are not limited to, statements regarding
the potential of its DeltEx Gamma-Delta T cells to target and kill
ovarian cancer; the broad applicability of INB-400; the use of
INB-400 in indications outside of brain tumors; the potential
synergy of combining gamma-delta T cells with chemotherapy to
target solid tumors across a broad range of cancer indications,
including ovarian cancer; the development and continued progress of
IN8bio’s preclinical and clinical product candidates, including
INB-100, INB-200, and INB-400; and the timing of initiation,
progress and scope of clinical trials; and IN8bio’s ability to
achieve anticipated milestones, including expected data readouts
from its trials, enrollment of additional patients in its clinical
trials and advancement of clinical development plans. IN8bio may
not actually achieve the plans, intentions or expectations
disclosed in these forward-looking statements, and you should not
place undue reliance on these forward-looking statements. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in these forward-looking
statements as a result of various factors, including: risks to site
initiation, clinical trial commencement, patient enrollment and
follow-up, as well as IN8bio’s ability to meet anticipated
deadlines and milestones, presented by the ongoing COVID-19
pandemic as well as rising inflation and regulatory developments;
uncertainties inherent in the initiation and completion of
preclinical studies and clinical trials and clinical development of
IN8bio’s product candidates; the risk that IN8bio may not realize
the intended benefits of its DeltEx platform; availability and
timing of results from preclinical studies and clinical trials;
whether the outcomes of preclinical studies will be predictive of
clinical trial results; whether initial or interim results from a
clinical trial will be predictive of the final results of the trial
or the results of future trials; the risk that trials and studies
may be delayed and may not have satisfactory outcomes; potential
adverse effects arising from the testing or use of IN8bio’s product
candidates; expectations for regulatory approvals to conduct trials
or to market products; IN8bio’s reliance on third parties,
including licensors and clinical research organizations; and other
important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, are
described in greater detail in the section entitled “Risk Factors”
in our Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission (SEC) on May 12, 2023, as well as in other
filings IN8bio may make with the SEC in the future. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and IN8bio expressly disclaims any
obligation to update any forward-looking statements contained
herein, whether because of any new information, future events,
changed circumstances or otherwise, except as otherwise required by
law.
Company Contact:IN8bio, Inc.Patrick McCall+ 1
646.600.6GDT (6438)info@IN8bio.com
Investors & Media Contact: Argot
PartnersIN8bio@argotpartners.com
IN8bio (NASDAQ:INAB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
IN8bio (NASDAQ:INAB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024